WSJ.com
SOLX 790 laser equivalent to argon laser trabeculoplasty (ALT) for IOP reduction while preserving trabecular meshwork
WALTHAM, Mass., Sept 18, 2008 /PRNewswire via COMTEX/ -- SOLX, Inc. announced today U.S. Food and Drug (FDA) 510(k) clearance for the SOLX 790 to perform Titanium:Sapphire laser trabeculoplasty (TLT). The 510(k) clearance was based on the results of a multi-center, international clinical trial that established equivalency of TLT to ALT in the ability to reduce intraocular pressure (IOP) in patients having primary open angle glaucoma and poorly controlled IOP on maximally tolerated medications and/or prior failed trabeculoplasty. The laser had previously been approved for sale in Europe and Canada.